摘要
索拉菲尼是一种多激酶抑制剂,用于治疗晚期肾细胞癌及其他实体肿瘤。索拉菲尼常见不良反应之一为手足皮肤反应(HFSR),发生率为33.8%,临床表现为手足麻木感、麻刺感、红斑、皮肤发疱、发干、皲裂、脱屑。索拉菲尼致HFSR的发病机制尚不清楚,可能与抑制VEGF、PDGF、c-kit、RET及FLT3有关。HFSR的防治包括根据手足皮肤反应程度调整剂量及对症治疗。
Sorafenib is a muhikinase inhibitor, which is used in the treatment of advanced renal cell carcinoma and many other types of solid tumors. One of the most common adverse reactions to sorafenib is hand-foot skin reaction （HFSR）. The incidence of HFSR is 33.8%. The clinical manifestations of HFSR are numbness, tingling, erythema, swelling, blister, dry skin, chap, and desquamation on the hands and feet. The mechanisms of sorafenib-induced HFSR is unclear, but may be related to inhibition of VEGF, PDGF, c-kit, RET, and FLT3. Prevention and treatment of HFSR include dosage adjustment according to the intensity of HFSR and symptomatic treatment.
出处
《药物不良反应杂志》
2009年第3期188-190,共3页
Adverse Drug Reactions Journal
关键词
索拉菲尼
多激酶制剂剂
手足皮肤反应
防治
sorafenib
muhikinase inhibitor
hand-foot skin reaction
prevention and treatment
